Purpose: Approximately 8 percent of all testicular tumours are non-germ-cel
l tumours. LEYDIG-cell-tumours, 10% of which are malignant, form a consider
able part of these. The problem, however, is that there are no histo-pathol
ogical criteria of the malignancy. The malignancy is only proven by the met
astasation. On the basis of the tumours, which were observed here, a risk-f
actor is worked out.
Material and Methods: in the period from 1992 to 1997, 20 LEYDIG-cell-tumou
rs in the Armed Forces Hospital Hamburg and in the General Hospital Harburg
were treated. 4 of these patients had metastases. 1 patient had pulmonal a
nd cerebral metastases, 1 patient had retroperitoneal and pulmonal metastas
es, 2 patients had retroperitoneal and intraabdominal metastases. These 4 p
atients have died. The clinical parameters such as tumour-size, gynaecomast
ia and parameters of fertility were compared. The levels and the kinetics o
f the parameters Estradiol, Testosteron, LH, FSH were reevaluated using sta
tistical methods.
Results: No significant difference between metastasized and non-metastasize
d tumours regarding the clinical parameters and the laboratory-findings cou
ld be found. A significant difference, however, emerged with regard to age
at the time of the illness. The metastasized patients were between 42 and 6
6 years old (median 45 years) and the non-metastasized between 22 and 51 ye
ars (median 29 years). This difference is significant mathematically (p=0.0
02).
Conclusion: The path of metastasation of the LEYDIG-cell-tumours resembles
that of germ-cell-tumours. Since there is no cure by chemotherapy or by rad
iation, the only chance is that of radical surgery. Should each LEYDIG-cell
-tumour be referred to retroperitoneal lymph node dissection (RPLND)? On th
e basis of the potential introduced here, we think, that RPLND for all pati
ents with LNDIG-cell-tumours, who are older than 40 years, must be offered.
Whether the eradication of the last tumor-cell will be successful, is an o
pen question.